ArticleFrontiers in cell and developmental biology2021
CLEC4s as Potential Therapeutic Targets in Hepatocellular Carcinoma Microenvironment.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method.Frontiers in endocrinology · 2023Pooled it
- Liquid biopsy-based multi-omics approach for early detection of hepatocellular carcinoma (ASCEND-Hep): a multiphase prospective development and validation study.BMC medicine · 2026Article
- The asialoglycoprotein receptor 1 (ASGR1): emerging new roles in health and disease.Biomarker research · 2026Review
- CLEC4D as an Effective Indicator for Assessing Severity of Illness in Critically Ill Patients: A Prospective Study.International journal of general medicine · 2026Article
- Chronic obstructive pulmonary disease reprograms the lung into an immune organ through trained immunity, cell death networks, and immune checkpoint dysregulation.Frontiers in medicine · 2026Article
- Aflatoxin B1 Impairs TACE Efficacy Through Downregulated Carbonic Anhydrase 2: A Bioinformatics Analysis.International journal of genomics · 2026Article
- Construction and validation of risk models of prognostic genes associated with parthanatos in papillary thyroid carcinoma based on bioinformatics.Discover oncology · 2025Article
- Targeting CLEC4E in immunosuppressive tumour-associated macrophages via BET inhibition.Clinical and translational medicine · 2025Article
- Validation of signature molecular profiles of advanced HCV liver disease in hepatocellular carcinoma patients.Virus research · 2025Article
- A High-Throughput Cell-Based Luciferase Reporter Assay for Identifying Inhibitors of ASGR1.International journal of molecular sciences · 2025Article
- Potential diagnostic marker gene set for non-alcoholic steatohepatitis associated hepatocellular carcinoma with lymphocyte infiltration.Translational cancer research · 2025Article
- Integration of single-cell sequencing and mendelian randomization reveals novel causal pathways between monocytes and hepatocellular carcinoma.Discover oncology · 2025Article
- Gut colonization ofMicrobiology spectrum · 2025Article
- Transcriptomic profiling reveals macrophage gene signatures associated with lactylation-related pathways in chronic obstructive pulmonary disease.Frontiers in genetics · 2025Article
- CLEC4G Reverses Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing PD-1 Expression via the Wnt/International journal of genomics · 2025Article
- Asialoglycoprotein receptor 1: a multifaceted receptor in the liver and cardiovascular system.Frontiers in medicine · 2025Review
- Article
- Association between novel genetic variants of Notch signaling pathway genes and survival of hepatitis B virus-related hepatocellular carcinoma.Cancer medicine · 2024Article
- The C-type lectin DCIR contributes to the immune response and pathogenesis of colorectal cancer.Scientific reports · 2024Article
- CLEC4E upregulation in gastric cancer: A potential therapeutic target correlating with tumor-associated macrophages.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppressive tumor microenvironment in hepatocellular carcinoma (HCC) is critical in tumor development. C-type (Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.